Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Facilitating the Behavioral Treatment of Cannabis Use Disorder

To see complete record on, please visit this link

Id: NCT02946489

Organisation Name: New York State Psychiatric Institute

Overal Status: Completed

Start Date: October 2016

Last Update: February 11, 2020

Lead Sponsor: New York State Psychiatric Institute

Brief Summary: Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use. Cannabis use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this single blind open-label trial is to test the feasibility of administering glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based relapse prevention (MBRP) for cannabis use disorders.

  • Cannabis Dependence

Total execution time in seconds: 0.3011589050293